...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The International journal of oral & maxillofacial implants >Evaluation of Clinical Parameters and Levels of Proinflammatory Cytokines in the Crevicular Fluid Around Dental Implants in Patients with Type 2 Diabetes Mellitus
【24h】

Evaluation of Clinical Parameters and Levels of Proinflammatory Cytokines in the Crevicular Fluid Around Dental Implants in Patients with Type 2 Diabetes Mellitus

机译：2型糖尿病患者牙种植体周围龈沟液中促炎细胞因子临床参数和水平的评估

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Diabetes mellitus is considered a relative contraindication for dental implant therapy, depending on levels of glycemic control. The purpose of this research was to evaluate the peri-implant conditions and measure the levels of interleukin 1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF-alpha) in the peri-implant crevicular fluid (PICF) in patients with glycemic-controlled type 2 diabetes (T2DM). Materials and Methods: Thirteen patients with well-controlled T2DM and seven systemically healthy patients were recruited for this study. Clinical measurements were recorded, and samples of gingival crevicular fluid (GCF) and PICF were collected from the sulci of both adjacent teeth and implants at baseline (after implant placement), 1 month, 4 months, and 7 months. Levels of IL-1 beta and TNF-alpha in the GCF and PICF were analyzed by enzyme-linked immunosorbent assay. Standardized intraoral radiographs were taken at baseline (after implant placement), 4 months, and 7 months. Implant stability was assessed by resonance frequency analysis at baseline, at 1 month, and at 4 months. Results: Glycosylated hemoglobin levels in the T2DM group were significantly increased at 7 months compared to baseline levels. Implant stability quotient levels at 4 months were increased significantly compared to baseline in both groups. Alveolar bone levels around implants were statistically lower at 4 and 7 months compared to baseline and statistically decreased at 7 months compared to 4 months in the T2DM group. There were no significant differences between groups in bone levels around implants, and no significant differences were found in levels of IL-1 beta and TNF-alpha at either teeth or implants or between the groups. Conclusion: The results suggest that dental implant therapy can be offered to patients with well-controlled T2DM, as there were no significant differences between control and diabetic patients in terms of clinical parameters or GCF and PICF cytokine levels.
机译：目的：根据血糖控制水平，糖尿病被认为是牙种植体治疗的相对禁忌症。这项研究的目的是评估种植体周围患者的病情，并测量种植体周围患者胎体液（PICF）中白介素1 beta（IL-1 beta）和肿瘤坏死因子α（TNF-alpha）的水平。血糖控制的2型糖尿病（T2DM）。材料和方法：招募了13例控制良好的T2DM患者和7例系统健康患者。记录临床测量结果，并在基线（植入物放置后），1个月，4个月和7个月时，从相邻牙齿和植入物的龈沟收集龈沟液（GCF）和PICF。通过酶联免疫吸附测定法分析了GCF和PICF中IL-1β和TNF-α的水平。在基线（植入物放置后），4个月和7个月时进行标准化的口腔X光片检查。在基线，1个月和4个月时通过共振频率分析评估植入物的稳定性。结果：与基线水平相比，T2DM组的糖化血红蛋白水平在7个月时显着增加。两组患者在4个月时的植入物稳定性商水平均显着高于基线。在T2DM组中，植入物周围的牙槽骨水平在第4和7个月与基线相比在统计学上较低，而在7个月与4个月相比在统计学上降低。各组之间植入物周围的骨水平无显着差异，牙齿或植入物或各组之间的IL-1β和TNF-α水平也无显着差异。结论：该结果表明，对于控制良好的T2DM患者，可以提供牙种植体治疗，因为对照和糖尿病患者在临床参数或GCF和PICF细胞因子水平方面无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号